According to a phase 2 trial, camrelizumab, an anti-PD–1 antibody, plus famitinib, a multitargeted tyrosine kinase inhibitor against VEGFR2/3, improved the overall survival of patients with recurrent or metastatic cervical cancer when compared to either camrelizumab alone, or investigator’s choice of chemotherapy.

Xiaohua Wu, MD, Shanghai Cancer Center at Fudan University, Shanghai, China, presented these survival outcome results with extended follow-up at the Society of Gynecologic Oncology 2024 Annual Meeting on Women’s Cancers in San Diego, California.

According to Dr Wu and coauthors, “the prognosis of recurrent or metastatic cervical cancer remains dismal” and there is a lack of effective treatment options. Previously it has been reported that camrelizumab plus famitinib “improved antitumor activity compared with camrelizumab alone or the investigator’s choice of chemotherapy.”

In this open-label study, 194 patients with recurrent or metastatic cervical cancer who had relapsed or progressed after platinum-based chemotherapy were enrolled. Patients were randomized to receive 200 mg camrelizumab every 3 weeks plus 20 mg famitinib once a day (n = 105), camrelizumab alone (n = 54), or investigator’s choice of chemotherapy every 3 weeks (n = 35).

Previous results, with a median follow-up duration of 9.9 months, found the combination of camrelizumab plus famitinib improved the objective response rate and PFS compared with camrelizumab alone and investigator’s choice of chemotherapy. At that time, OS data was immature. This current analysis had a median follow-up duration of 13.6 months. The median OS of the camrelizumab plus famitinib arm was 20.6 months, compared with 14.9 months in the camrelizumab alone arm, and 13.9 months in the chemotherapy arm. The risk of death in the camrelizumab plus famitinib arm was reduced by 33% when compared with the camrelizumab alone arm, and by 45% when copared with the chemotherapy arm. The 12-month OS rates were 76.1%, 67.2%, and 58.4%, respectively. There were no new safety signals observed.

Dr Wu et al concluded these results “further support...this regimen as a novel treatment option for [recurrent or metastatic cervical cancer.”

Source:

Wu X, Xia L, Zhang K, et al. Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy for recurrent or metastatic cervical cancer. Presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancers; March 16-18, 2024. San Diego, California.